Amadix
Amadix is focused on developing and commercializing innovative cancer diagnostic technologies that address unmet medical needs in oncology. The company's flagship product, Colofast, is a non-invasive screening signature for colorectal cancer and advanced adenoma diagnosis, aimed at reducing the high mortality rate associated with colon cancer. Amadix's approach emphasizes early detection, allowing for timely treatment while avoiding the complications of invasive procedures like tumor biopsies. The team comprises industry veterans with extensive expertise in oncology diagnostics, the pharmaceutical industry, and biotechnology, supported by independent board members who provide strategic guidance in commercialization and business development, particularly in Europe and the United States. Amadix's products undergo rigorous analytical validation and clinical studies before being introduced to the global market.
Transbiomed is a biotechnology company based in Barcelona, Spain, specializing in non-invasive molecular diagnostic therapies. The company has developed a urine test aimed at the early diagnosis of prostate cancer, offering a potential alternative to traditional biopsy methods. Transbiomed is currently seeking funding to initiate clinical validation of its innovations in various hospitals across Spain. The firm focuses on biomarker discovery and development, advancing its products through industrial prototyping, final design, and pivotal clinical trials, with the intention of licensing its technology to larger pharmaceutical companies for commercialization.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.